Luis Mendez Castellanos
Internal Medicine · New York, NYNPI 1457491961
Payments from drug & device makers
Across 180 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$462
- Novo Nordisk$456
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- AstraZeneca$140
- Amarin Pharma, Inc.$121
- plus $605 from 15 others
What the payments were for
- Food & beverage$3,377100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,432 |
| Amgen(2 entities) | 23 | $462 |
| Novo Nordisk | 24 | $456 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| AstraZeneca | 8 | $140 |
| Amarin Pharma, Inc. | 6 | $121 |
| Bayer | 6 | $108 |
| Lilly USA, LLC | 5 | $94 |
| Aimmune Therapeutics, Inc. | 2 | $52 |
| Nestle Healthcare Nutrition Inc. | 2 | $50 |
| Exact Sciences | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| GSK | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $29 |
| Redhill Biopharma Inc. | 1 | $26 |
| Merck | 2 | $25 |
| Novartis | 1 | $23 |
| VBI Vaccine (delaware) Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
How this compares
$3,377 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 109 | $89,403 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $77,549 |
| JanuviaSitagliptin Phosphate | 40 | $53,935 |
| JardianceEmpagliflozin | 51 | $53,405 |
| RybelsusSemaglutide | 13 | $34,059 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $23,102 |
| Diclofenac Sodium | 152 | $16,721 |
| EliquisApixaban | 21 | $15,702 |
| CreonLipase/Protease/Amylase | 56 | $11,766 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 229 | $11,234 |
| XareltoRivaroxaban | 11 | $9,963 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $9,514 |
| Atorvastatin Calcium | 674 | $8,516 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,495 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 173 | $5,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $25 | $131,484109 claims |
| AbbVieLinzess, Creon | $1,432 | $101,170165 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $29 | $58,90063 claims |
| Novo NordiskRybelsus | $456 | $34,05913 claims |
| Aimmune Therapeutics, Inc.Zenpep | $52 | $2,18916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.